Supplementary Material for: Efficacy of lipophilic statins on outcomes of patients treated with immune checkpoint inhibitors

Statins are associated with improved survival outcomes in patients receiving immune checkpoint inhibitors (ICIs), but the impact of different statins on outcomes is unknown. We conducted a retrospective cohort study to investigate if statins with lipophilic properties are associated with improved clinical outcomes in patients treated with ICIs. There were 51 lipophilic statin users, 25 hydrophilic statin users, and 658 non-users. Lipophilic statin users had a longer median OS (38.0 [IQR, 16.7-not reached] vs. 15.2 [IQR, 8.2–not reached] months vs. 18.9 [IQR, 5.4-51.6] months) and PFS (13.0 [IQR, 4.7–41.5] vs. 8.2 [IQR, 2.2–14.7] months vs. 5.6 [2.3-18.7] months) than hydrophilic statin users and non-statin users. In Cox proportional hazard analyses, the use of lipophilic statins was associated with a 40-50% lower risk of mortality and disease progression compared with hydrophilic statin or non-statin users. In conclusion, the use of lipophilic statins seems to be associated with survival benefits in patients undergoing immunotherapy.

他汀类药物与接受免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）治疗的患者获得更佳生存结局存在关联，但不同他汀类药物对治疗结局的影响尚不明确。本研究开展了一项回顾性队列研究，旨在探究亲脂性他汀类药物是否与接受ICIs治疗的患者获得更佳临床结局相关。本队列共纳入51名亲脂性他汀类药物使用者、25名亲水性他汀类药物使用者以及658名非他汀类药物使用者。亲脂性他汀类药物使用者的中位总生存期（Overall Survival, OS）为38.0个月[四分位间距（Interquartile Range, IQR），16.7~未达到]，长于亲水性他汀类药物使用者的15.2个月[四分位间距，8.2~未达到]与非他汀类药物使用者的18.9个月[四分位间距，5.4~51.6个月]；其中位无进展生存期（Progression-Free Survival, PFS）为13.0个月[四分位间距，4.7~41.5]，同样长于亲水性他汀类药物使用者的8.2个月[四分位间距，2.2~14.7]与非他汀类药物使用者的5.6个月[四分位间距，2.3~18.7]。在Cox比例风险回归分析中，与亲水性他汀类药物使用者或非他汀类药物使用者相比，使用亲脂性他汀类药物可使死亡与疾病进展风险降低40%~50%。综上，在接受免疫治疗的患者中，使用亲脂性他汀类药物似乎可带来生存获益。